ProCE Banner Activity

HELIOS: Longer PFS With Addition of Ibrutinib to Bendamustine/Rituximab in Previously Treated CLL/SLL

Slideset Download
Conference Coverage
New phase III results from the HELIOS trial of ibrutinib plus BR in previously treated CLL/SLL.

Released: June 05, 2015

Expiration: June 03, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Celgene

Genentech BioOncology

Incyte

Novartis Pharmaceuticals Corporation